Senior Management:

Leonard P. Ruiz Jr., Ph.D. Chief Executive Officer, President, and Director. A nationally recognized expert in biotechnology and business development with 29 years of experience in developing leading edge technologies into successful businesses. International experience (World Bank, USAID) and formerly CEO of The SOTA TEC Fund in Minneapolis, and President of Global Genomics Capital, Inc in Los Angeles.

Dennis K. Anderson, M.Sc. Vice President. With over 21 years of experience in research and commercial development of biotechnology and pharmaceutical products, Mr. Anderson's expertise includes preclinical pharmacology and toxicology/safety, human clinical studies, manufacturing, quality assurance, and regulatory affairs.

Scott E. Rosenow, Esq. Vice President of Operations. Mr. Rosenow has had broad experience in the biosciences field. His expertise is in business development, strategic alliances, technology transfer, legal issues, and project management. Prior to his involvement in the biosciences, he practiced regulatory law in Washington D.C. for over 12 years. He received his BA and JD from the University of Minnesota.

Kevin H. Roche, Esq., MBA. Vice President, General Counsel and Director. Formerly Senior Vice President UNITEDHEALTH GROUP, Minneapolis and was also with Partners National Health Plans and American Medcenters, Inc. Senior executive proficient in large, small and startup company situations. Skilled in major transactions; legal, regulatory and governmental affairs and comprehensive health care operations and policy.

Lex Lee, Pharm.D. Managing Director, Business Development-Asia. Dr. Lee has a Doctorate of Pharmacy degree from University of Southern California, and has extensive management experience in the pharmaceutical/biotechnology industry and technology transfer in Asia. He is a founder of several Asian biotech companies.

Chairman, Scientific Advisory Board:

Bruce F. Mackler, Ph.D., J.D. Chair of Scientific Advisory Board. Dr. Mackler's 23 years of FDA legal/regulatory experience in biomedical products includes biologics, drugs, medical and in vitro diagnostic devices. Dr. Mackler also provides effective counsel regarding certain biological vaccine, biotechnology, SNPs and other advance technology matters, as well as technology licensing, material transfer and outsourcing agreements. He has a Ph.D. in Immunology/Microbiology and has authored more than 100 scientific papers and abstracts focusing on the immunology/immunochemistry aspects of diseases, as well as numerous articles and briefing papers on FDA and FDA-related legal and regulatory issues concerning product development and FDA approval/licensure.